Simulations Plus, Inc. (NASDAQ:SLP) announced a new strategic collaboration program with three major pharmaceutical companies, integrating its model‑informed and AI‑accelerated tools—GastroPlus, ADMET Predictor, and MonolixSuite—into the partners’ drug‑development pipelines. The partnership is designed to embed SLP’s AI‑enhanced modeling capabilities directly into the clients’ scientific workflows, creating a “show‑me” moment that could accelerate adoption of SLP’s software and services.
The collaboration will allow SLP to embed its AI‑driven workflows into the partners’ research and development processes, enabling more efficient and accurate simulation of drug absorption, distribution, metabolism, and toxicity. By working closely with these pharma clients, SLP aims to deepen customer engagement, increase cross‑selling opportunities, and generate additional revenue streams from both software licenses and consulting services.
Jonathan Chauvin, Co‑Chief Product & Technology Officer, said, “Our approach to AI is grounded in how it operates within a complete system, not as a standalone capability. These collaborations will allow us to work alongside our partners, leveraging real‑time scientific feedback and company data to continuously refine how workflows are orchestrated across our tools, ensuring AI‑driven efficiencies translate into reproducible, traceable outcomes. The insights we gain will directly shape how we evolve our platform and deliver value at scale.” Shawn O’Connor, Chief Executive Officer, added, “The partnerships represent a move from experimentation to practical implementation of AI in drug development.”
In its most recent quarterly report, SLP reported earnings per share of $0.13, below the consensus estimate of $0.18, while revenue reached $18.42 million, surpassing the consensus estimate of $18.05 million. The earnings miss and revenue beat reflect the company’s ongoing investment in AI capabilities and the strong demand for its software solutions, even as operating costs continue to rise.
The collaborations are a key component of SLP’s broader strategic reset, which seeks to unify product development, scientific R&D, and business development after its largest acquisition. By embedding its AI platform into the pipelines of major pharma companies, SLP positions itself to capture new revenue opportunities and strengthen its competitive stance in the biosimulation market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.